Cleveland Clinic

Bridge to Life Announces Late-Breaker, Oral and Poster Presentations on Bridge to HOPE trial with VitaSmart at 2024 American Transplant Congress (ATC) in Philadelphia, PA, June 1-5, 2024

Retrieved on: 
星期三, 五月 8, 2024
University, Safety, Clinical trial, The, HOPE, Hope, Perfusion, Abstract, Cleveland Clinic, ATC, University of Iowa, Dietary supplement

CHICAGO, May 8, 2024 /PRNewswire/ -- Bridge to Life Ltd, a renowned market leader in organ preservation solutions, today announced acceptance of four abstracts based on data from its U.S. pivotal clinical trial on HOPE using the VitaSmart Liver Machine, including a late-breaker, for presentation at the 2024 annual meeting of the American Transplant Congress (ATC). The conference is scheduled to take place in Philadelphia, PA from June 1-5, 2024. VitaSmart is not currently approved for use in the US.

Key Points: 
  • The conference is scheduled to take place in Philadelphia, PA from June 1-5, 2024.
  • VitaSmart is not currently approved for use in the US.
  • Three presentations will be oral, including a late-breaker, and one will be a poster presentation.
  • June 4 (Poster Session): Economic Assessment Of Hypothermic Oxygenated Machine Perfusion In Liver Transplantation: Interim Analysis, D. Axelrod, University of Iowa, Iowa City, IA et al.

neurocare group AG appoints Tariq El-Titi as Senior Vice President MENA, strengthening commitment to Middle East health sector

Retrieved on: 
星期二, 五月 7, 2024
Janus, Investment, Dubai Healthcare City, Health, Cleveland Clinic, AG, Growth, Senior, GCC, Mental health, Cleveland Clinic Abu Dhabi, Management

DUBAI, UAE, May 7, 2024 /PRNewswire/ -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best practice, today announced the appointment of Tariq El-Titi as Senior Vice President for the Middle East and North-Africa (MENA) region.

Key Points: 
  • Tariq is a seasoned healthcare specialist, bringing with him a wealth of experience in healthcare start-up ventures and strategic C-level leadership roles.
  • Throughout his career, Tariq has worked in various private and publicly listed multinationals, semi-government organizations, and start-up companies across the UK, Europe, and the Middle East.
  • Focused on bringing disruptive new health technologies to the Middle East, Tariq founded Janus Ventures in 2018, underscoring his commitment to driving innovation in the healthcare sector.
  • "We warmly welcome Tariq to the neurocare team," said Thomas Mechtersheimer, CEO of neurocare Group AG.

neurocare group AG appoints Tariq El-Titi as Senior Vice President MENA, strengthening commitment to Middle East health sector

Retrieved on: 
星期二, 五月 7, 2024
Janus, Investment, Dubai Healthcare City, Health, Cleveland Clinic, AG, Growth, Senior, GCC, Mental health, Cleveland Clinic Abu Dhabi, Management

DUBAI, UAE, May 7, 2024 /PRNewswire/ -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best practice, today announced the appointment of Tariq El-Titi as Senior Vice President for the Middle East and North-Africa (MENA) region.

Key Points: 
  • Tariq is a seasoned healthcare specialist, bringing with him a wealth of experience in healthcare start-up ventures and strategic C-level leadership roles.
  • Throughout his career, Tariq has worked in various private and publicly listed multinationals, semi-government organizations, and start-up companies across the UK, Europe, and the Middle East.
  • Focused on bringing disruptive new health technologies to the Middle East, Tariq founded Janus Ventures in 2018, underscoring his commitment to driving innovation in the healthcare sector.
  • "We warmly welcome Tariq to the neurocare team," said Thomas Mechtersheimer, CEO of neurocare Group AG.

The Aesthetic Foundation Welcomes Dr. Onelio Garcia Jr. as President

Retrieved on: 
星期日, 五月 5, 2024
Education, General surgery, Aesthetics, Jews, Surgeon, Patient safety, Child, Face, Aesthetic Surgery Journal, Saint Louis University, Journal, Breast cancer, Plastic, SSBI, Loyola University Medical Center, Woman, Lymphedema, McGuire family, DRS, Breast implant, Cleveland Clinic, Executive Committee, Mortality, Faculty, Calendar, University, Hospital, Safety, Publication, Private practice, Research, Trustee, Loma Linda University, Health, Student, Plastic surgery, Division, Synthetic control method, Elective surgery, Patient, Gravity anomaly, Clinical professor, Dentistry

VANCOUVER, BC, May 5, 2024 /PRNewswire/ -- The Aesthetic Foundation, formerly known as the Aesthetic Surgery Education and Research Foundation (ASERF), proudly announces the election of Dr. Onelio Garcia Jr. "Oni", as its new President. Dr. Garcia's appointment heralds an exciting chapter for The Foundation as it continues its mission to improve the safety and effectiveness of aesthetic surgery and medicine following a successful rebranding earlier this year.

Key Points: 
  • VANCOUVER, BC, May 5, 2024 /PRNewswire/ -- The Aesthetic Foundation, formerly known as the Aesthetic Surgery Education and Research Foundation (ASERF), proudly announces the election of Dr. Onelio Garcia Jr. "Oni", as its new President.
  • An official rollout of The Aesthetic Foundation rebranding was unveiled at The Aesthetic Meeting 2024 in Vancouver, Canada this week along with a new website, TheAestheticFoundation.org .
  • Dr. Garcia, a board-certified aesthetic plastic surgeon based in Miami, Florida brings a wealth of experience and a dedication to patient safety.
  • His leadership is poised to guide The Aesthetic Foundation in its renewed mission, building upon the strong foundation established over 30 years ago as ASERF.

Studies Find Erectile Dysfunction Commercial Bias Is More Prevalent On TikTok Than YouTube

Retrieved on: 
星期六, 五月 4, 2024
Urology, Social media, Bias, American Urological Association, Abstract (summary), Abstract, Cleveland Clinic, MD, Research, Erectile dysfunction, Patient, Annual general meeting, SAN, Bariatric surgery

SAN ANTONIO, May 04, 2024 (GLOBE NEWSWIRE) -- Abstracts being presented at the American Urological Association's Annual Meeting discuss how urologists need to continue to remain relevant on social media to counteract misinformation and commercial bias on erectile dysfunction.

Key Points: 
  • SAN ANTONIO, May 04, 2024 (GLOBE NEWSWIRE) -- Abstracts being presented at the American Urological Association's Annual Meeting discuss how urologists need to continue to remain relevant on social media to counteract misinformation and commercial bias on erectile dysfunction.
  • Researchers will present their study findings covering important updates on sexual function in San Antonio, TX, from May 3 to 6.
  • Petar Bajic, MD, urologist and director of men’s health at the Cleveland Clinic, moderated a virtual press session with the abstract authors, providing key insights into their research.
  • “We also are going to see how bariatric surgery for obese patients may have an impact on their sex lives.”
    The following abstracts are covered in the moderated panel:

KARL STORZ and Well Lead Medical Announce Exclusive Agreement for Distribution of ClearPetra Stone-Removal System in the U.S.

Retrieved on: 
星期四, 五月 2, 2024
Health Technology, Health, Medical Devices, Well, MIT Tech Talk, Urology, Kidney, American Urological Association, Marketing, Cleveland Clinic, MD, PCNL, Gynaecology, FRCSC, Stone, Booth, Master of Science, AUA, KARL, Research institute, Pharmaceutical industry

KARL STORZ United States announces an exclusive agreement with Well Lead Medical to offer the ClearPetra suction-evacuation ureteral access sheath in conjunction with KARL STORZ endoscopic visualization devices for comprehensive urinary stone management.

Key Points: 
  • KARL STORZ United States announces an exclusive agreement with Well Lead Medical to offer the ClearPetra suction-evacuation ureteral access sheath in conjunction with KARL STORZ endoscopic visualization devices for comprehensive urinary stone management.
  • “Our strategic collaboration with Well Lead Medical on ClearPetra represents a major step forward in stone management.
  • “The collaboration between Well Lead Medical and KARL STORZ represents a significant milestone in our commitment to advancing endourology.
  • During the show, KARL STORZ will be sponsoring a Tech Talk on May 4, 10:00–10:25 a.m., at Booth #1733.

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing

Retrieved on: 
星期四, 五月 2, 2024
Johns Hopkins University, University, Mayo Clinic, Cancer, SOS, American College, Case Western Reserve University, AUC, ACG, Esophageal cancer, Prevalence, Methylation, Risk, Barrett's esophagus, Cleveland Clinic, American Journal, Lucid, Adenocarcinoma, National Cancer Institute, NPV, NGS, University of North Carolina, Gold, Detection, EGD, Patient, Research report, NCI, PPV, Medicare, Manuscript, GERD, Guideline, Gastroesophageal reflux disease, Medical imaging

NEW YORK, May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the peer-reviewed publication of positive data from a National Cancer Institute (NCI)-sponsored, prospective, multicenter clinical validation study assessing the performance of Lucid's EsoGuard® Esophageal DNA Test on samples collected with its EsoCheck® Esophageal Cell Collection Device. This case-control study, led by Case Western Reserve University's Amitabh Chak, M.D., was funded through the NCI's Barrett's Esophagus Translational Research Network (BETRNet), and included renowned investigators from leading academic medical centers, including Case Western Reserve University, Mayo Clinic, Johns Hopkins University, Washington University in St. Louis, University of North Carolina, and Cleveland Clinic. EsoGuard demonstrated unprecedented early precancer detection compared to the gold standard of upper endoscopy (EGD). The manuscript, entitled Multicenter, Prospective Trial of Non-Endoscopic Biomarker-Driven Detection of Barrett's Esophagus And Esophageal Adenocarcinoma, was published in the American Journal of Gastroenterology, the leading clinical journal covering gastroenterology published on behalf of the American College of Gastroenterology (ACG).

Key Points: 
  • EsoGuard demonstrated unprecedented early precancer detection compared to the gold standard of upper endoscopy (EGD).
  • Dr. Aklog concluded, "The publication of the BETRNet study is the culmination of a period of rapid expansion of EsoGuard's clinical evidence base.
  • It represents the second peer-reviewed, and third overall, clinical validation study demonstrating consistently excellent EsoGuard performance.
  • Soon to be released data from a fourth such clinical validation study tells the same story.

Six recipients from across Canada recognized for their ground-breaking work and excellence in Innovation - Governor General's Innovation Awards

Retrieved on: 
星期二, 四月 30, 2024
Royal Society of Canada, Royal Society, Rideau Hall, Bowhead whale, Rideau Hall Foundation, Ecosystem, Cardiac surgery, Disability, Research, Bacteria, Moral development, Cleveland Clinic, Innovation, Health Canada, The Economist, Artificial intelligence, Carbon, Digital economy, Reach, Humanities, Entrepreneurship, Future, Behavior, RHF, Survivor, Journalism, Food, University, Social science, Committee, Universities Canada, Diagnosis, Government, Quality of life, Graves (surname), Organization, Nursing

OTTAWA, ON, April 30, 2024 /CNW/ - Today the Rideau Hall Foundation (RHF) announced the recipients of the ninth annual Governor General's Innovation Awards (GGIA).

Key Points: 
  • OTTAWA, ON, April 30, 2024 /CNW/ - Today the Rideau Hall Foundation (RHF) announced the recipients of the ninth annual Governor General's Innovation Awards (GGIA).
  • These awards recognize and celebrate exceptional Canadian individuals, teams and organizations for their excellence in innovation and their contributions in helping to shape our future and positively impact our quality of life.
  • The recipients of the 2024 Governor General's Innovation Awards are:
    Following a snowboarding accident, Christian Bagg recognized the limitations of existing assistive technology for people with disabilities.
  • Inneo is a revolution in the food world, being the first bacteriocin approved by Health Canada to eliminate bacteria from food.

Fujifilm Introduces First-of-its-Kind Transducer for On-Pump Intracardiac Echocardiography Imaging (OPIE) for Septal Myectomy

Retrieved on: 
星期五, 四月 26, 2024
FDA, Cardiothoracic surgery, AATS, TTE, Tech, Ventricular septal defect, Heart, Cleveland Clinic, Facial muscles, MD, Doctor of Philosophy, NYU, FACS, Indocyanine green, Cardiology, Fujifilm, OPIE, TEE, Division, Medical imaging

Lexington, MA,, April 26, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, announced the launch of its first-of-kind OPIE Transducer for on-pump intracardiac echocardiography (OPIE) for septal myectomy.

Key Points: 
  • Lexington, MA,, April 26, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, announced the launch of its first-of-kind OPIE Transducer for on-pump intracardiac echocardiography (OPIE) for septal myectomy.
  • However, with OPIE, a thin transducer is passed into the heart during the myectomy where images of the patient’s septal thickness can be seen in real-time.
  • A study featuring Fujifilm’s OPIE Transducer highlights that the system provides established imaging to aid in septal myectomy procedures compared to TEE and transthoracic echocardiogram (TTE).
  • Real-time measurements of the interventricular septal thickness are crucial during septal myectomy to avoid creating a ventricular septal defect while resecting enough myocardium.

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications

Retrieved on: 
星期三, 四月 17, 2024
Equity, Research, Cleveland Clinic, Doctor of Philosophy, Gastroparesis, KOL, Senior, Incidence, Metoclopramide, Research fellow

SOLANA BEACH, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced it will host a virtual KOL and investor webinar on Wednesday, April 24 at 12:00 p.m.

Key Points: 
  • SOLANA BEACH, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced it will host a virtual KOL and investor webinar on Wednesday, April 24 at 12:00 p.m.
  • ET.
  • Moderated by Yale Jen, PhD, Senior Managing Director of Equity Research at Laidlaw Capital Markets, the event will feature Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic and prescriber of GIMOTI will provide his expert opinion and insights on Evoke’s recently presented healthcare resource utilization data, patient experience with GIMOTI and the rising incidence of gastroparesis due to the increased use GLP-1 based medications.